Clinical Trial Update: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of the antibody-drug conjugate MYTX-011 in non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MYTX-011

Snippet

Sponsor: Mythic Therapeutics | Conditions: NSCLC, NSCLC Stage IV | Phase 1 | Status: TERMINATED